231 related articles for article (PubMed ID: 22622825)
1. Curcumin protects nigral dopaminergic neurons by iron-chelation in the 6-hydroxydopamine rat model of Parkinson's disease.
Du XX; Xu HM; Jiang H; Song N; Wang J; Xie JX
Neurosci Bull; 2012 Jun; 28(3):253-8. PubMed ID: 22622825
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective Effect of Curcumin on the Nigrostriatal Pathway in a 6-Hydroxydopmine-Induced Rat Model of Parkinson's Disease is Mediated by α7-Nicotinic Receptors.
El Nebrisi E; Javed H; Ojha SK; Oz M; Shehab S
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33023066
[TBL] [Abstract][Full Text] [Related]
3. [The protective effect of ginsenoside Rg1 on dopaminergic neurons of substantia in the ovariectomized rat model of Parkinson's disease].
Xu L; Liu LX; Chen WF; Xie JX; Huang WX
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2008 Feb; 24(1):1-5. PubMed ID: 21141541
[TBL] [Abstract][Full Text] [Related]
4. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
Liu H; Jia L; Chen X; Shi L; Xie J
Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective effects of garlic extract on dopaminergic neurons of substantia nigra in a rat model of Parkinson's disease: motor and non-motor outcomes.
Bigham M; Mohammadipour A; Hosseini M; Malvandi AM; Ebrahimzadeh-Bideskan A
Metab Brain Dis; 2021 Jun; 36(5):927-937. PubMed ID: 33656625
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Sleeman IJ; Boshoff EL; Duty S
Neuropharmacology; 2012 Dec; 63(7):1268-77. PubMed ID: 22971544
[TBL] [Abstract][Full Text] [Related]
7. Neurorescue effect of rosmarinic acid on 6-hydroxydopamine-lesioned nigral dopamine neurons in rat model of Parkinson's disease.
Wang J; Xu H; Jiang H; Du X; Sun P; Xie J
J Mol Neurosci; 2012 May; 47(1):113-9. PubMed ID: 22205146
[TBL] [Abstract][Full Text] [Related]
8. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease.
Xue YQ; Zhao LR; Guo WP; Duan WM
Neuroscience; 2007 May; 146(3):1245-58. PubMed ID: 17363174
[TBL] [Abstract][Full Text] [Related]
9. The effects simultaneous inhibition of dipeptidyl peptidase-4 and P2X7 purinoceptors in an in vivo Parkinson's disease model.
Jamali-Raeufy N; Mojarrab Z; Baluchnejadmojarad T; Roghani M; Fahanik-Babaei J; Goudarzi M
Metab Brain Dis; 2020 Mar; 35(3):539-548. PubMed ID: 32016817
[TBL] [Abstract][Full Text] [Related]
10. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
Oiwa Y; Yoshimura R; Nakai K; Itakura T
Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
[TBL] [Abstract][Full Text] [Related]
11. Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease.
Stayte S; Rentsch P; Li KM; Vissel B
PLoS One; 2015; 10(4):e0124325. PubMed ID: 25902062
[TBL] [Abstract][Full Text] [Related]
12. Curcumin protects nigrostriatal dopaminergic neurons and reduces glial activation in 6-hydroxydopamine hemiparkinsonian mice model.
Tripanichkul W; Jaroensuppaperch EO
Int J Neurosci; 2012 May; 122(5):263-70. PubMed ID: 22176529
[TBL] [Abstract][Full Text] [Related]
13. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
14. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Youdim MB; Stephenson G; Ben Shachar D
Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
[TBL] [Abstract][Full Text] [Related]
15. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
16. Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease.
Thornton E; Vink R
PLoS One; 2012; 7(4):e34138. PubMed ID: 22485158
[TBL] [Abstract][Full Text] [Related]
17. [Protective effect of alkaloids from Piper longum in rat dopaminergic neuron injury of 6-OHDA-induced Parkinson's disease].
Zheng L; Wang H; Ba YY; Liu HL; Wang M; Guo WW; Wu X; Yang H
Zhongguo Zhong Yao Za Zhi; 2014 May; 39(9):1660-5. PubMed ID: 25095380
[TBL] [Abstract][Full Text] [Related]
18. Nerve growth factor increases survival of dopaminergic graft, rescue nigral dopaminergic neurons and restores functional deficits in rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Agrawal AK
Neurosci Lett; 2006 May; 398(1-2):44-9. PubMed ID: 16423459
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
20. Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation.
Carbone M; Duty S; Rattray M
BMC Neurosci; 2012 Apr; 13():38. PubMed ID: 22480308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
